Zainab A, Shabbir D, Waqar K, Mehmood A. Consumption of Cannabis: A Risk Factor or a Therapeutic Agent for Patients with Schizophrenia. Cognizance of Schizophrenia:: A Profound Insight into the Psyche 2023. [DOI: 10.1007/978-981-19-7022-1_15][Reference Citation Analysis]
2
Salehi A, Namaei P, TaghaviZanjani F, Bagheri S, Moradi K, Khodaei Ardakani MR, Akhondzadeh S. Adjuvant palmitoylethanolamide therapy with risperidone improves negative symptoms in patients with schizophrenia: A randomized, double-blinded, placebo-controlled trial. Psychiatry Res 2022;316:114737. [PMID: 35917650 DOI: 10.1016/j.psychres.2022.114737][Cited by in F6Publishing: 1][Reference Citation Analysis]
Zuccoli GS, Brandão-teles C, Vieira GM, Gomes FV, Crunfli F. Molecular Findings Guiding the Modulation of the Endocannabinoid System as a Potential Target to Treat Schizophrenia. Advances in Experimental Medicine and Biology 2022. [DOI: 10.1007/978-3-030-97182-3_7][Reference Citation Analysis]
